ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective.

Gastrointestinal Neoplasms / drug therapy Humans Immunotherapy Medical Oncology
colorectal cancer neuroendocrine tumours oesophagus cancer pancreatic cancer stomach cancer

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
04 2022
Historique:
received: 01 12 2021
revised: 22 12 2021
accepted: 23 12 2021
pubmed: 19 2 2022
medline: 4 5 2022
entrez: 18 2 2022
Statut: ppublish

Résumé

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Identifiants

DOI: 10.1016/j.esmoop.2022.100392 PMID: 35180656 PMC: PMC8857487
pubmed: 35180656
pii: S2059-7029(22)00012-6
doi: 10.1016/j.esmoop.2022.100392
pmc: PMC8857487
pii:
doi:

Types de publication

Congress Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

100392

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Disclosure TK discloses consulting or advisory role for Merck Sharp & Dohme (MSD), Bristol Myers Squibb (BMS), Lilly, Roche, Boehringer Ingelheim, and Servier. MA discloses consulting or advisory role for MSD, BMS, Lilly, and Servier. RO discloses consulting or advisory role for BMS, Merck, MSD, and Servier; Speakers Bureau for BMS, Eli Lilly, Merck, Roche, and Servier, and received Travel Grants from BMS, Merck and Servier. JWV discloses consulting or advisory role for Agios, AstraZeneca, Delcath Systems, Keocyt, Genoscience Pharma, Incyte, Ipsen, Merck, Mundipharma EDO, Novartis, PCI Biotech, Pfizer, Pieris Pharmaceuticals, QED, and Wren Laboratories; Speakers Bureau for Imaging Equipment Limited, Ipsen, Novartis, Nucana; and received Travel Grants from Celgene and Nucana. All other authors have declared no conflicts of interest.

Auteurs

T Koessler (T)

Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland. Electronic address: Thibaud.kossler@hcuge.ch.

M Alsina (M)

Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.

D Arnold (D)

Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany.

I Ben-Aharon (I)

Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel.

M Collienne (M)

Department of Oncology, Haematology and Palliative Care, Asklepios Klinik Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.

M P Lutz (MP)

Caritasklinikum, Saarbrucken, Germany.

C Neuzillet (C)

GI Oncology, Medical Oncology Department, Institut Curie Saint-Cloud, Versailles Saint Quentin University, Saint-Cloud, France.

R Obermannova (R)

Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno; Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

M Peeters (M)

Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium.

F Sclafani (F)

Department of Medical Oncology, Institut Jules Bordet-Université Libre de Bruxelles (ULB), Brussels, Belgium.

E Smyth (E)

Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

J W Valle (JW)

Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

A D Wagner (AD)

Department of Oncology, Division of Medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.

L Wyrwicz (L)

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

E Fontana (E)

Sarah Cannon Research Institute, London, UK.

M Moehler (M)

Department of Internal Medicine, Johannes-Gutenberg University, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Tumeurs gastro-intestinales › ESMO Congress 2021: highlights from the EORTC...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › ESMO Congress 2021: highlights from the EORTC...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › ESMO Congress 2021: highlights from the EORTC...
questionsmedicales.fr › Professions de santé › Médecine › Médecine interne › Oncologie médicale › ESMO Congress 2021: highlights from the EORTC...